The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator–Induced Intracerebral Hemorrhage After Thromboembolic Stroke
Authors:
- 1 January 2002
- journal article
- other
- Published by Wolters Kluwer Health in Stroke
- Vol. 33 (1) , 147-152
Abstract
Background and Purpose— Platelet activation and deposition in brain microvessels appear to be key events in the pathogenesis of ischemia-induced neuronal degeneration and behavioral deficits. It ha...Keywords
This publication has 22 references indexed in Scilit:
- Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trialAmerican Heart Journal, 2000
- Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseJACC, 2000
- Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatmentCatheterization and Cardiovascular Interventions, 2000
- Open label tissue plasminogen activator for stroke: The Oregon experienceJournal of Stroke and Cerebrovascular Diseases, 1999
- Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.Journal of Clinical Investigation, 1998
- Acute Hypertension, but Not Thrombolysis, Increases the Incidence and Severity of Hemorrhagic Transformation Following Experimental Stroke in RabbitsExperimental Neurology, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Tissue plasminogen activator‐mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbitsNeurology, 1989
- Tissue Plasminogen ActivatorArchives of Neurology, 1988
- Intracerebral Hemorrhage After Experimental Embolic InfarctionArchives of Neurology, 1987